Nucleic Acid Nanomaterials-based Therapy for Osteoarthritis: Progress and Prospects

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Rheumatology

Background:

• Osteoarthritis (OA) is a prevalent degenerative joint disease affecting over 300 million people globally, characterized by complex pathological mechanisms involving multiple signaling pathways.
• The significant societal and economic burden of OA necessitates the development of novel and effective therapeutic strategies.
• Current treatments for OA often focus on symptom management rather than addressing the underlying disease pathology.

Approach:

• This review explores the application of nucleic acid nanomaterials in OA therapy, focusing on their unique properties such as small size, biocompatibility, and structural versatility.
• Investigates the use of various nucleic acids, delivered either independently or via vectors, to modulate OA pathogenesis and progression.
• Highlights the dual role of nucleic acid nanomaterials as therapeutic agents and drug delivery vehicles for OA treatment.

Key Points:

• Nucleic acid nanomaterials offer precise therapeutic interventions by targeting specific molecular pathways involved in OA.
• Their inherent biocompatibility and tunable structure allow for tailored drug delivery systems to enhance treatment efficacy.
• The ability of these nanomaterials to enter cells, with or without vectors, is crucial for their therapeutic action in OA.

Conclusions:

• Nucleic acid nanomaterials represent a promising frontier in OA therapeutics, offering high therapeutic efficiency and drug-carrying capabilities.
• The development of nucleic acid nanomaterial-based therapies holds significant potential for improving the management of osteoarthritis.
• Continued research in this area is expected to yield advanced treatment options for the millions affected by OA.